Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine

Core Insights - Xtant Medical Holdings, Inc. has announced the sale of certain Coflex® and CoFix® interlaminar stabilization implant assets and all OUS entities of Paradigm Spine GmbH to Companion Spine, LLC for a total consideration of approximately $19.2 million [1][2] - The transaction is expected to close in the third quarter of 2025 and aims to enhance Xtant's focus on its core business while improving its balance sheet and liquidity [2][3] Financial Details - The proceeds from the transaction consist of $11 million in cash at closing and $8.2 million in short-term seller financing [2][4] - Xtant plans to use the proceeds to reduce long-term debt and improve cash liquidity [2] Strategic Focus - The transaction allows Xtant to concentrate on the development of higher-margin orthobiologics, thereby streamlining operations [3] - Companion Spine, backed by Viscogliosi Brothers, is expected to effectively manage the transitioned products and drive their growth [3] Operational Transition - Certain members of Xtant's U.S. and international commercial organizations will transition to Companion Spine to continue supporting the products [2] - Companion Spine aims to enhance its product solutions portfolio and strengthen its presence in the U.S. market [3][8] Closing Conditions - The transaction is subject to Companion Spine obtaining financing and other customary closing conditions [3]